IBO (Impact BioMedical, Inc.) Stock Analysis - Hedge Fund Holdings
Impact BioMedical, Inc. (IBO) is a publicly traded Healthcare sector company. As of May 21, 2026, IBO trades at $0.53 with a market cap of $58.04M and a P/E ratio of -1.52. IBO moved -0.02% today. Year to date, IBO is +3.30%; over the trailing twelve months it is -3.03%. Its 52-week range spans $0.36 to $6.17. Rallies surfaces IBO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who owns IBO stock?
Rallies tracks hedge fund and 13F ownership for IBO, including fund holders, share counts, and position changes when data is available.
Macko Todd D sold 43.40K (~$24.37K) on Mar 27, 2026.
Macko Todd D sold 1.60K (~$961.28) on Mar 25, 2026.
Grady Jason sold 50.00K (~$32.51K) on Mar 23, 2026.
IBO Analyst Consensus
IBO analyst coverage data. Average price target: $0.00.
Common questions about IBO
Who owns IBO stock?
Rallies tracks hedge fund and 13F ownership for IBO, including fund holders, share counts, and position changes when data is available.
Does Rallies show 13F holders for IBO?
Yes. Rallies tracks hedge fund and 13F ownership data for IBO, including fund names, share counts, latest tracked quarter, and position changes when available.
Is IBO research on Rallies investment advice?
No. Rallies provides research, data, and educational context for IBO. It does not provide personalized investment advice.
